迈向有效的疟疾疫苗。
Towards an effective malaria vaccine.
作者信息
Aide Pedro, Bassat Quique, Alonso Pedro L
机构信息
National Institute of Health, Ministry of Health, Mozambique.
出版信息
Arch Dis Child. 2007 Jun;92(6):476-9. doi: 10.1136/adc.2005.092551.
Abstract
An effective malaria vaccine may be developed in the near future
摘要
一种有效的疟疾疫苗可能在不久的将来研制出来。
相似文献
1
Towards an effective malaria vaccine.迈向有效的疟疾疫苗。
Arch Dis Child. 2007 Jun;92(6):476-9. doi: 10.1136/adc.2005.092551.
2
Malaria vaccines: where are we and where are we going?疟疾疫苗：我们目前的状况以及未来的发展方向？
Lancet Infect Dis. 2002 Dec;2(12):737-43. doi: 10.1016/s1473-3099(02)00451-6.
3
Malaria vaccine development: persistent challenges.疟疾疫苗研发：持续面临的挑战。
Curr Opin Immunol. 2012 Jun;24(3):324-31. doi: 10.1016/j.coi.2012.03.009. Epub 2012 Apr 21.
4
Immune evasion by malaria parasites: a challenge for vaccine development.疟原虫的免疫逃避：疫苗研发面临的挑战
Curr Opin Immunol. 2009 Jun;21(3):321-30. doi: 10.1016/j.coi.2009.05.015. Epub 2009 Jun 1.
5
Overview of plant-made vaccine antigens against malaria.植物源疟疾疫苗抗原概述。
J Biomed Biotechnol. 2012;2012:206918. doi: 10.1155/2012/206918. Epub 2012 Jul 15.
6
Adjuvants and malaria vaccine development.
Chem Immunol. 2002;80:343-65. doi: 10.1159/000058854.
7
Whole parasite vaccines for the asexual blood stages of Plasmodium.针对疟原虫无性血阶段的全寄生虫疫苗。
Immunol Rev. 2020 Jan;293(1):270-282. doi: 10.1111/imr.12819. Epub 2019 Nov 10.
8
Malaria vaccines and their potential role in the elimination of malaria.疟疾疫苗及其在消除疟疾方面的潜在作用。
Malar J. 2008 Dec 11;7 Suppl 1(Suppl 1):S10. doi: 10.1186/1475-2875-7-S1-S10.
9
Betting on a malaria vaccine.押注于疟疾疫苗。
N Engl J Med. 2005 Nov 3;353(18):1877-81. doi: 10.1056/NEJMp058217.
10
Mosquito-based transmission blocking vaccines for interrupting Plasmodium development.基于蚊子的传播阻断疫苗，用于阻断疟原虫发育。
Microbes Infect. 2008 Jul;10(8):845-9. doi: 10.1016/j.micinf.2008.05.004. Epub 2008 May 22.
引用本文的文献
1
Global prevalence and determinants associated with the acceptance of monkeypox vaccination.猴痘疫苗接种接受度的全球流行率及相关决定因素。
Narra J. 2024 Aug;4(2):e866. doi: 10.52225/narra.v4i2.866. Epub 2024 Jul 17.
2
Global Prevalence and Potential Influencing Factors of COVID-19 Vaccination Hesitancy: A Meta-Analysis.新冠疫苗接种犹豫的全球流行率及潜在影响因素：一项荟萃分析
Vaccines (Basel). 2022 Aug 19;10(8):1356. doi: 10.3390/vaccines10081356.
3
Pre-Erythrocytic Vaccines against Malaria.抗疟疾的红细胞前期疫苗。
Vaccines (Basel). 2020 Jul 21;8(3):400. doi: 10.3390/vaccines8030400.
4
Malaria endemicity and co-infection with tissue-dwelling parasites in Sub-Saharan Africa: a review.撒哈拉以南非洲地区的疟疾流行情况及与组织内寄生寄生虫的共感染：综述
Infect Dis Poverty. 2015 Aug 29;4:35. doi: 10.1186/s40249-015-0070-0.
5
Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.植物细胞包封的人用生物制药、自身抗原和疫苗抗原的口服递送。
Adv Drug Deliv Rev. 2013 Jun 15;65(6):782-99. doi: 10.1016/j.addr.2012.10.005. Epub 2012 Oct 23.
6
Approaching the target: the path towards an effective malaria vaccine.接近目标：走向有效疟疾疫苗的道路。
Mediterr J Hematol Infect Dis. 2012;4(1):e2012015. doi: 10.4084/MJHID.2012.015. Epub 2012 Mar 10.
7
Histopathological effects of sub-chronic lamivudine-artesunate co-administration on the liver of diseased adult Wistar rats.亚慢性拉米夫定-青蒿琥酯联合给药对患病成年Wistar大鼠肝脏的组织病理学影响。
N Am J Med Sci. 2011 Jul;3(7):325-8. doi: 10.4297/najms.2011.3325.
8
Naturally acquired IgG antibodies against the C-terminal part of Plasmodium falciparum sporozoite threonine-asparagine-rich protein in a low endemic area.在低流行地区，针对恶性疟原虫孢子蛋白 C 末端苏氨酸-天冬酰胺丰富区的天然获得性 IgG 抗体。
Parasitol Res. 2011 Aug;109(2):315-20. doi: 10.1007/s00436-011-2257-z. Epub 2011 Feb 1.
9
Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response.多等位基因 PfAMA1 疫苗诱导体液免疫应答；佐剂和成分等位基因数量对反应广度的影响。
PLoS One. 2010 Nov 3;5(11):e15391. doi: 10.1371/journal.pone.0015391.
10
Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery.叶绿体衍生疫苗抗原通过口服或注射给药可同时预防霍乱和疟疾。
Plant Biotechnol J. 2010 Feb;8(2):223-42. doi: 10.1111/j.1467-7652.2009.00479.x. Epub 2009 Dec 28.
本文引用的文献
1
A review of human vaccine research and development: malaria.人类疫苗研发综述：疟疾
Vaccine. 2007 Feb 19;25(9):1567-80. doi: 10.1016/j.vaccine.2006.09.074. Epub 2006 Oct 5.
2
Immune responses to asexual blood-stages of malaria parasites.对疟原虫无性血液阶段的免疫反应。
Curr Mol Med. 2006 Mar;6(2):187-203. doi: 10.2174/156652406776055212.
3
Immune response to pre-erythrocytic stages of malaria parasites.对疟原虫红细胞前期阶段的免疫反应。
Curr Mol Med. 2006 Mar;6(2):169-85. doi: 10.2174/156652406776055249.
4
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.在肯尼亚西部成年人中开展的1期随机双盲安全性和免疫原性试验，该试验用AS02A佐剂的恶性疟原虫裂殖子表面蛋白FMP1疫苗。
Vaccine. 2007 Jan 2;25(1):176-84. doi: 10.1016/j.vaccine.2005.11.037. Epub 2005 Dec 7.
5
Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.RTS,S/AS02A疟疾疫苗预防莫桑比克儿童恶性疟原虫病的保护期：一项随机对照试验的单盲延长随访
Lancet. 2005 Dec 10;366(9502):2012-8. doi: 10.1016/S0140-6736(05)67669-6.
6
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.顶端膜抗原1的1期临床试验：一种用于恶性疟原虫疟疾的无性血液期疫苗。
Infect Immun. 2005 Jun;73(6):3677-85. doi: 10.1128/IAI.73.6.3677-3685.2005.
7
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.间日疟原虫疟疾传播阻断疫苗Pvs25H的1期疫苗试验
Vaccine. 2005 May 2;23(24):3131-8. doi: 10.1016/j.vaccine.2004.12.019.
8
Filling the vaccine gap.填补疫苗缺口。
Lancet Infect Dis. 2005 Jan;5(1):7. doi: 10.1016/s1473-3099(04)01235-6.
9
Genetically modified Plasmodium parasites as a protective experimental malaria vaccine.转基因疟原虫作为一种保护性实验性疟疾疫苗。
Nature. 2005 Jan 13;433(7022):164-7. doi: 10.1038/nature03188. Epub 2004 Dec 5.
10
Pregnancy-associated malaria and the prospects for syndrome-specific antimalaria vaccines.妊娠相关疟疾及针对特定综合征的抗疟疾疫苗的前景
J Exp Med. 2004 Nov 1;200(9):1093-7. doi: 10.1084/jem.20041974.
Zotero 插件